Drug intelligence / Profile preview

ALK 014

Development stage: Preclinical
Lead developer: ALK Abelló

Overview

ALK 014 is an investigational biologic drug candidate being developed by ALK (ALK-Abelló) for the treatment of food allergies and other undisclosed indications. As a biologic, it represents an expansion of ALK's portfolio beyond its traditional focus on allergen-specific immunotherapy (AIT) tablets. While the specific biological target, mechanism of action, and clinical phase are not publicly disclosed in the company's pipeline, the drug is positioned as a key asset in ALK's strategy to address unmet needs in food allergy and explore new therapeutic areas.

Beyond the preview

Go deeper on ALK 014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALK 014.

Explore the full profile